Targeting Polo-like Kinase 1 in Acute Myeloid Leukemia

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2015 Apr 2

PMID 25830015

Citations 17

Authors

Joseph M Brandwein

Affiliations

Soon will be listed here.

Abstract

Polo-like kinase 1 (Plk1) plays a number of important roles in the passage of cells through mitosis. It is expressed at high levels in a variety of malignancies, including acute myeloid leukemia (AML). Inhibition of Plk1 results in cell cycle arrest and apoptosis, and has anti-tumor effects in pre-clinical models. A number of Plk1 inhibitors have been developed, some of which have entered clinical trials. Of these, volasertib (BI6727) has been most extensively studied clinically in AML. Volasertib has demonstrated antileukemic activity in AML, both as a single agent and when combined with low-dose cytarabine. It is well tolerated, with the major toxicity being reversible myelosuppression. A recently completed phase III clinical trial in older AML patients will address the question of whether adding this agent to low-dose cytarabine is associated with a survival advantage.

Citing Articles

Constitutive activation of the Src-family kinases Fgr and Hck enhances the tumor burden of acute myeloid leukemia cells in immunocompromised mice.

Shu S, Chen L, Gonzalez-Areizaga G, Smithgall T Sci Rep. 2025; 15(1):174.

PMID: 39747387 PMC: 11697302. DOI: 10.1038/s41598-024-83740-6.

Only Infant -Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Fischer J, Erkner E, Radszuweit P, Hentrich T, Keppeler H, Korkmaz F Int J Mol Sci. 2024; 25(23).

PMID: 39684470 PMC: 11641557. DOI: 10.3390/ijms252312760.

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

He M, Cao C, Ni Z, Liu Y, Song P, Hao S Signal Transduct Target Ther. 2022; 7(1):181.

PMID: 35680848 PMC: 9178337. DOI: 10.1038/s41392-022-00999-9.

Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia.

Bi L, Jia S, Hu W, Su X, Chen X, Tang H BMC Med Genomics. 2022; 15(1):101.

PMID: 35501867 PMC: 9063138. DOI: 10.1186/s12920-022-01251-7.

Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma.

Qian Y, Li Y, Chen K, Liu N, Hong X, Wu D J Inflamm Res. 2022; 15:1099-1116.

PMID: 35210814 PMC: 8859474. DOI: 10.2147/JIR.S347732.

References

Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp J, Hoffmann M . The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol. 2007; 17(4):304-15. DOI: 10.1016/j.cub.2006.12.046. View

Dai W, Wang Q, Traganos F . Polo-like kinases and centrosome regulation. Oncogene. 2002; 21(40):6195-200. DOI: 10.1038/sj.onc.1205710. View

Olmos D, Barker D, Sharma R, Brunetto A, Yap T, Taegtmeyer A . Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011; 17(10):3420-30. DOI: 10.1158/1078-0432.CCR-10-2946. View

Gumireddy K, Reddy M, Cosenza S, Boominathan R, Boomi Nathan R, Baker S . ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005; 7(3):275-86. DOI: 10.1016/j.ccr.2005.02.009. View

Winkles J, Alberts G . Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene. 2005; 24(2):260-6. DOI: 10.1038/sj.onc.1208219. View

Mrozek K, Marcucci G, Nicolet D, Maharry K, Becker H, Whitman S . Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30(36):4515-23. PMC: 3518729. DOI: 10.1200/JCO.2012.43.4738. View

Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R . Prognostic value of pololike kinase expression in melanomas. JAMA. 2000; 283(4):479-80. DOI: 10.1001/jama.283.4.479. View

Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30(21):2670-7. PMC: 4874148. DOI: 10.1200/JCO.2011.38.9429. View

Craig S, Wyatt M, McInnes C . Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014; 9(7):773-89. DOI: 10.1517/17460441.2014.918100. View

10.

Komrokji R, Raza A, Lancet J, Ren C, Taft D, Maniar M . Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013; 162(4):517-24. PMC: 4685467. DOI: 10.1111/bjh.12436. View

11.

Renner A, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A . Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009; 114(3):659-62. DOI: 10.1182/blood-2008-12-195867. View

12.

Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K . A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009; 23(9):1564-76. DOI: 10.1038/leu.2009.94. View

13.

Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S . The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013; 8(3):e58424. PMC: 3592825. DOI: 10.1371/journal.pone.0058424. View

14.

Liu L, Zhang M, Zou P . Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007; 48(11):2179-83. DOI: 10.1080/10428190701615918. View

15.

van Vugt M, van de Weerdt B, Vader G, Janssen H, Calafat J, Klompmaker R . Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem. 2004; 279(35):36841-54. DOI: 10.1074/jbc.M313681200. View

16.

Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M . BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007; 17(4):316-22. DOI: 10.1016/j.cub.2006.12.037. View

17.

Chopra P, Sethi G, Dastidar S, Ray A . Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs. 2009; 19(1):27-43. DOI: 10.1517/13543780903483191. View

18.

Liu X, Erikson R . Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003; 100(10):5789-94. PMC: 156279. DOI: 10.1073/pnas.1031523100. View

19.

Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J . Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2014; 90(1):27-30. PMC: 4276516. DOI: 10.1002/ajh.23858. View

20.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D . NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012; 11(4):1006-16. DOI: 10.1158/1535-7163.MCT-11-0765. View